Results 141 to 150 of about 1,039,492 (280)
Relationships between periodontitis, tooth loss, and metabolic syndrome indicators
Abstract Background This study investigates how poor oral health impacts metabolic alterations, specifically evaluating the effects of periodontitis and tooth loss, either individually or in combination, on the number of metabolic syndrome (MetS) indicators.
Verbênia Silva Conceição +14 more
wiley +1 more source
Alteraciones psicopatológicas en epilepsia infantil e intervención terapéutica
Noelia Martínez Menéndez +3 more
doaj +1 more source
Abstract Objectives To describe the clinical and laboratory characteristics and outcomes of pediatric hepatopulmonary syndrome (HPS) secondary to portal hypertension (PH) in Brazil. Methods Fifty‐four pediatric patients diagnosed with PH and HPS according to the European Respiratory Society criteria were included in this multicenter retrospective study.
Leticia Drumond Alberto +14 more
wiley +1 more source
Treatment for acquired aplasia and refractory cytopenia. Review of a historical cohort
Jesús González de Pablo +4 more
doaj +1 more source
Jesús Navarro Botella (1881-?), maestro racionalista, activista anarquista y editor
Antoni Dalmau i Ribalta
openalex +2 more sources
INTRODUCCIÓN A LA TEOLOGÍA DE JESÚS ESPEJA. UN TEÓLOGO PARA HOY ENRAIZADO EN LA TRADICIÓN
Iván Mejía Correa
openalex +2 more sources
ABSTRACT Background and Objective Palliative surgery in oncology aims to relieve symptoms, improve quality of life, and respect patient autonomy in advanced cancer. This study aimed to develop evidence‐based recommendations for safely indicating and performing palliative surgeries in Brazil, considering clinical, ethical, and multidisciplinary aspects.
Audrey Cabral Ferreira de Oliveira +15 more
wiley +1 more source
Francisco E. Peña-Sandoval +2 more
openaire +2 more sources
ABSTRACT Background Baricitinib is a selective Janus kinase (JAK)1/JAK2 inhibitor approved in more than 70 countries for the treatment of moderate‐to‐severe atopic dermatitis (AD) in adults, and in over 30 countries for adolescents and children from age 2 years with moderate‐to‐severe AD, who are candidates for systemic therapy.
Antonio Costanzo +11 more
wiley +1 more source

